SCPH
Closed
Scpharmaceuticals Inc
3.92
+0.11 (+2.89%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.81
Day's Range: 3.78 - 3.99
Send
sign up or login to leave a comment!
When Written:
9.21
Scpharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes innovative products for the treatment and management of various diseases. The company is headquartered in Burlington, Massachusetts, and was founded in 2013. Its primary focus is on developing and commercializing products for the treatment of heart failure, infectious diseases, and cancer.
Scpharmaceuticals' lead product candidate is Furoscix, a subcutaneous formulation of furosemide for the treatment of congestion in patients with heart failure. The company is also developing products for the treatment of infections caused by multidrug-resistant organisms and for the treatment of cancer.
The company's mission is to develop innovative products that improve patient outcomes and reduce healthcare costs. Scpharmaceuticals is committed to working with healthcare providers, payers, and patients to improve the delivery of healthcare and enhance patient care.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Scpharmaceuticals' lead product candidate is Furoscix, a subcutaneous formulation of furosemide for the treatment of congestion in patients with heart failure. The company is also developing products for the treatment of infections caused by multidrug-resistant organisms and for the treatment of cancer.
The company's mission is to develop innovative products that improve patient outcomes and reduce healthcare costs. Scpharmaceuticals is committed to working with healthcare providers, payers, and patients to improve the delivery of healthcare and enhance patient care.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








